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The problem of tumor hypoxia has been recognized and studied by the oncology community for over 60 years. From radiation and chemotherapy resistance to the increased risk of metastasis, low oxygen concentrations in tumors have caused patients with many types of tumors to respond poorly to conventional cancer therapies. It is clear that patients with high levels of tumor hypoxia have a poorer overall treatment response and that the magnitude of hypoxia is an important prognostic factor. As a result, the development of methods to measure tumor hypoxia using invasive and noninvasive techniques has become desirable to the clinical oncology community. A variety of imaging modalities have been established to visualize hypoxia in vivo. Positron emission tomography (PET) imaging, in particular, has played a key role for imaging tumor hypoxia because of the development of hypoxia-specific radiolabelled agents. Consequently, this technique is increasingly used in the clinic for a wide variety of cancer types. Following a broad overview of the complexity of tumor hypoxia and measurement techniques to date, this article will focus specifically on the accuracy and reproducibility of PET imaging to quantify tumor hypoxia. Despite numerous advances in the field of PET imaging for hypoxia, we continue to search for the ideal hypoxia tracer to both qualitatively and quantitatively define the tumor hypoxic volume in a clinical setting to optimize treatments and predict response in cancer patients. Ó 2014 by Radiation Research Society
INTRODUCTION
Tumor hypoxia is a characteristic of solid tumors and has been recognized as a crucial factor impacting cancer treatment effectiveness since its discovery (1) (2) (3) . Hypoxia occurs because the high rate of oxygen demanded and consumed by the tumor cells, stroma and endothelial cells exceeds that of the supply which is diminished compared to the blood supply of normal tissue (4) . The tumor hypoxic microenvironment impairs response to chemotherapy and radiation treatment for cancer patients resulting in poor prognosis and a reduction in overall survival (5) . This is caused by the presence of hypoxia in the tumor and the associated cellular oxygen reduction, as well as hypoxiainduced factors that lead to increased tumor proliferation (tumor invasion and metastases) and a more aggressive tumor phenotype (poor differentiation and reduced apoptosis) (5) (6) (7) .
For these reasons, over the last 60 years invasive and noninvasive techniques have been developed to measure tumor hypoxia. Although no method is ideal, molecular imaging has become the most commonly used noninvasive modality. Positron emission tomography (PET), singlephoton emission computed tomography (SPECT), magnetic resonance imaging (MRI) and optical imaging have become useful tools to characterize the magnitude and variability of hypoxia within a tumor and to guide clinical treatment decisions (8, 9) . PET in particular has become a leader in hypoxia imaging. Several PET radiotracers have been developed and continue to be synthesized to visualize the extent of tumor hypoxia on a patient-specific basis (10) . It has been shown that several of these tracers, particularly nitroimidazoles, can directly and reproducibly identify the presence of hypoxia (11, 12) .
Pretreatment PET imaging for tumor hypoxia combined with quantitative methods for characterizing the hypoxic status of a tumor could allow the clinician to more precisely stratify patients for randomized clinical trials aimed at overcoming the treatment resistance conferred by tumor hypoxia or alter radiation therapy treatment plans. However, a major problem with PET imaging for tumor hypoxia to date is that currently implemented methods used to quantify the hypoxic fraction do not represent absolute tumor pO 2 values. Moreover, existing techniques are inconsistent between clinics, resulting in highly variable and potentially suboptimal methods for defining hypoxic tumor volumes. Improving methods of quantification would enable more accurate identification of inter-and intratumor variability in hypoxia and help the clinician combat increased tumor aggressiveness and improve poor prognosis for cancer patients. The aim of this article is to discuss the current status and promise of PET imaging for tumor hypoxia measurement in a clinical setting and how it can be used to improve the treatment of oncology patients.
TUMOR HYPOXIA AFFECTS CANCER THERAPY IN A COMPLEX WAY
Tumor hypoxia results from several tumor-specific traits as shown in Fig. 1 . These include: (I) chronic hypoxia caused by the limited-diffusion distance of oxygen from blood vessels to the tumor cells (;150-200 lm) (2); (II) acute hypoxia due to the perfusion-limited impairment of the vascular vessels by (a) their structural abnormality and (b) high interstitial pressure caused by the combination of fluid in the tumor matrix and the rapidly proliferating tumor cells leading to constriction of the intratumor vasculature (13) (14) (15) (16) (17) (18) ; and (III) tumor blood vessel traits such as a reduced vascular density and arteriolar supply, poor blood vessel networks, varied red blood cell flux and high blood viscosity (19) .
The adverse impact of tumor hypoxia on cancer treatment response is the result of the reduction in diffusion, perfusion and delivery of oxygen to cancer cells. Tumor hypoxia has been shown to have a negative impact on the effectiveness of radiation therapy. This resistance is attributed to a reduction in DNA damage under reduced oxygen conditions. There is an intrinsic oxygen dependence of radiationinduced DNA damage, which has a higher probability of chemical restoration under hypoxic conditions but may become permanent in the presence of oxygen (20) (21) (22) . As a result, the biological effect of megavoltage X-ray radiation is 2-3 times higher in the presence of oxygen (21, 23) . Reduction in cellular oxygen and nutrients also forms proteomic and genomic changes creating more mutant, adaptive and aggressive tumor cells (5, 16). However, clinical evidence suggests that hypoxia-induced treatment failure is more likely attributed to radiation resistance and not hypoxia-induced metastasis (24) . Consequently, the hypoxic fraction in tumors has been correlated with a negative treatment outcome (25, 26) and a reduction in overall survival (6, 24, (27) (28) (29) (30) .
In the 1990s, the tumor hypoxic environment (oxygen and delivery imbalance) was connected with many tumorspecific traits (31, 32) . The main effect of the reduced oxygen level was the increased production of hypoxiainducible factor 1 (HIF-1), a transcription factor that becomes active and regulates oxygen homeostasis under hypoxic conditions (32) . The influence of oxygen concentration on the activity of HIF-1 is mostly a result of a delicate balance between prolyl hydrolyase domain-containing proteins and the crucial role of the von HippelLindau tumor suppressor protein (31) . HIF-1 activates genes that upregulate glycolysis, angiogenesis, and enhances cell survival under oxidative stress resulting in a causal relationship between hypoxia and tumor metastasis and growth (33, 34) . Target genes include vascular endothelial growth factor (VEGF), facilitative glucose transporters (GLUTs), hexokinases (HKs), erythropoietin (EPO), carbonic anhydrase IX (CAIX) and all of these are targets of hypoxic prevention or identification. Therefore, these conditions created by hypoxia, and in turn HIF-1, lead to tumors that are more invasive and resistant to cancer treatments such as chemotherapy (32) .
Nearly all solid tumors are positive for some form of hypoxia (severe and intermediate levels) or anoxic (no oxygen present) cells and these areas are often heterogeneously distributed within the tumor (5) . The presence of hypoxia does not depend on tumor size, stage, pathology or nodal status (13) . Moreover, the prevalence of tumor
Tumor hypoxia is caused by several tumor-specific traits that result in chronic (diffusion-limited), acute (perfusion limited) hypoxia. In combination with tumor blood vessel abnormalities, tumor hypoxia is a highly complex biological mechanism, making it difficult to counteract with current treatment techniques. 336 hypoxia and its traits are not cancer type-specific and have been found in a wide range of human malignancies including cancers of the head and neck, prostate, rectum, breast, uterine cervix, as well as brain tumors, soft tissue sarcomas and malignant melanomas (6, 25, 26, (35) (36) (37) . Hockel et al. (6) showed a drastic decrease in the overall survival in cervical cancer patients with more hypoxic tumors due to hypoxia-induced increased invasiveness and chemoradiation resistance. Brizel et al. (37) also clinically demonstrated an increase in hypoxia-induced invasiveness through metastatic disease in soft tissue sarcoma patients. It is evident based on the biological complexity, prevalence and negative prognostic impact of tumor hypoxia in cancer patients that a measurement technique with the capability of detecting and quantifying hypoxia would have substantial clinical implications.
METHODS OF TUMOR HYPOXIA MEASUREMENT
Tumor hypoxia measurement can be divided into two categories, invasive and noninvasive. Invasive measurements are considered to be the ''gold standard'' because they provide a direct measure of oxygen concentration in tissue. Numerous studies using the Eppendorf pO2 electrode (38, 39) have found that real-time pO 2 measurements are correlated with negative survival in patients with various cancer types (6, 25, 26, (35) (36) (37) . Although still in use, the Eppendorf electrode is no longer in production or supported by the manufacturer. In 1999, the OxyLitee fiber-optic sensor (40) became available to provide pO 2 measurements but has not been validated in the clinical setting. Moreover, both methods are user dependent because the invasive technique requires practice and expertise (41) . The pO 2 values are also restricted by sampling error because hypoxia is heterogeneous and it is not possible to extract pO 2 measurements for the entire tumor. Therefore, the invasiveness of the procedure limits its use to measure changes in tumor hypoxia and makes it only useful for superficially-located or easily accessible tumors. Also, the electrode cannot differentiate necrotic and anoxic tissue regions of a tumor.
Immunohistochemical (IHC) staining is another invasive technique used to measure tumor hypoxia. This can be done by administering exogenous bioreductive nitroimidazole compounds, e.g., pimonidazole or EF5 (42, 43) , before biopsy that binds to hypoxic regions. IHC staining can also be used to detect hypoxia-specific overexpressed endogenous proteins, e.g., carbonic anhydrase IX (44) . However, similar to Eppendorf electrodes the tumor biopsy (even if multiple cores are taken) is not representative of the whole tumor pO 2 , and undersampling is once again a problem. Moreover, these methods generally provide information on the presence of the hypoxic regions (as opposed to necrotic ones) but not the location and size. As this IHC technique is invasive, repetitive measurement of changes in the hypoxic fraction after cancer treatment is not realistic in a clinical setting (45) .
By contrast, molecular imaging techniques can be used to perform noninvasive measurements of tumor hypoxia. These include MRI, SPECT, optical imaging and PET. Electron paramagnetic resonance (EPR) can also be used to directly measure oxygen in tissue (46, 47) . MRI techniques are based on contrast agents (endogenous or exogenous) and include techniques such as dynamic contract MRI (DCE-MRI), magnetic resonance spectroscopy (MRS) (48) and blood oxygen-dependent level (BOLD) imaging (49, 50) . Optical imaging techniques measure the optical absorption, scattering and fluorescence in a tissue (51) . Recent developments in PET have allowed it to surpass SPECT in the availability and number of hypoxia imaging agents. These include halogenated nitroimidazole PET agents such as 18 F and 124 I, as well as metallic agents such as [
64 Cu]-ATSM. The available PET tracers will be discussed below.
PET IMAGING TO IDENTIFY TUMOR HYPOXIA: CURRENT STATUS OF PET RADIOTRACERS
PET radiotracers consist of a radioisotope and a biologically significant molecule that is specific to the functional measurement, e.g., glucose for glucose metabolism (52).
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C, 15 O and 18 F are popular radioisotopes due to their short half-lives. In 1981, Chapman et al. (53) were the first to detect tumor hypoxia with nitroimidazole compounds and molecular imaging. The widespread use of PET for imaging hypoxia is made possible through the use of exogenous markers, hypoxia-specific agents that are reduced and covalently bind to intracellular macromolecules in the tumor in the absence of oxygen (54) . Figure 2 shows representative clinical images of PET radiotracers for tumor hypoxia. In nitroimidazoles, a common marker for hypoxia, the relationship between the binding of oxygen and oxygen tension, is directly correlated with cell retention of the tracer varying significantly over the same range of oxygen concentration that has the largest impact on radiosensitivity (52) . Table 1 provides an overview of PET radiotracer human studies published to date that have been used in human patients to image tumor hypoxia, as well as their clinical application and conclusions. These include several nitroimidazole radiotracers (10), such as 2-(2-nitro- (68) . So despite some clinical use with this agent, more studies are necessary to confirm if it is truly a hypoxiaspecific marker (69) .
Since its development (70), numerous studies, both preclinical and clinical, consider [ 18 F]-FMISO and PET imaging to be the most promising method for hypoxia quantification because this tracer binds in hypoxic cells selectively (57, 58, 71, 72) . As a result, it is a lead contender in the in vivo and clinical assessment of hypoxia and is the most extensively studied PET hypoxia tracer (73, 74 The schematic in Fig. 3 shows two potential therapeutic uses of hypoxia imaging in the clinical setting. It is widely accepted that PET imaging can: identify tumor hypoxia in cancer patients; predict prognosis to treatment (85, (87) (88) (89) (90) (91) (92) (93) (94) (95) ; and either stratify patients into responding and nonresponding groups or provide more targeted treatments for poor responders (86, (96) (97) (98) (99) (100) . Such a process could also prevent some patients from receiving unnecessary treatments and consequential side effects or support the use of hypoxiaselective drugs such as tirapazamine (98) or the hypoxic radiosensitizer nimorazole (100). However, a potential limitation of this application is that a single pretherapy scan (used to define hypoxic patient group) may be an inadequate measure of tumor hypoxia because oxygenation is a dynamic process and one single pretreatment imaging time point may not be adequate.
Lee et al. 18 F]-FMISO show the latter to be a similar or stronger predictor of outcome (77, 101) . This predictive information is vital because hypoxia is correlated with poor local control and a high incidence of metastasis (102 PET imaging of tumor hypoxia is also used to modify radiation therapy treatment to improve therapy outcomes, such as accelerated radiotherapy with carbogen and nicotinamide (ARCON) (103) and dose escalation (104, 105) . Lee et al. (106) showed in an 11 patient treatment planning feasibility study that boosting the hypoxic volume (GTV H ) was feasible based on [ (114) . Practical dose escalation strategies may therefore require serial imaging and adaptive planning which would be more feasible in a hypofractionation paradigm (115) . In addition, tumor hypoxia is diffusely distributed and thus heterogeneity can restrict the feasibility of defining a hypoxic subvolume (110) .
Some studies attempted to implement dose painting by numbers. However, the results yielded clinically implausible boost volumes to achieve the desired tumor control probability (116, 117) . Clinical implementation of dose painting is dependent on accurate quantification of the hypoxic region and the capability of delivering large dose gradients on small spatial scales, which may be challenging with current techniques (118) . This challenge in radiation delivery is of great concern during hypofractionated treatments due to increased radioresistance of the hypoxic fraction in these cases (119) . Moreover, simulations found that less dose was required for cell kill in a given PET voxel when based on oxygen concentration and not when based on treating the voxel as a homogenous level of hypoxia (120) . This suggests dose painting by numbers may be useful (121) , but can we get a reliable image of hypoxia? In a recent review article, Geets et al. (122) agreed that, although dose painting is an attractive concept, it is restricted by low contrast, high noise and poor spatial resolution of the PET image as well as degradation by errors in treatment delivery (set-up error and patient motion). Animal studies may make further investigation possible to PET imaging for tumor hypoxia is an essential part of radiation therapy treatment. However, there are still a number of important challenges that need to be overcome.
The Ideal PET Tracer for Tumor Hypoxia
The criteria for a selection of clinical PET radiotracer are outlined in Fig. 4 . It is evident that each PET tracer for hypoxia has positive and negative attributes. Even [ 18 F]-FMISO has its limitations despite wide clinical implementation. A PET tracer should be capable of providing both qualitative and quantitative measurements. The PET image should show hypoxia only, not regions of necrosis or normoxia and be representative of tumor cell pO 2 levels within the clinically relevant hypoxic range (e.g., 0-10 mmHg) irrespective of the tumor grade or cell type (10). Often tracers are only able to detect very low pO 2 levels, but the cells with ''intermediate'' levels of hypoxia can be more important than the maximally resistant cells in determining tumor response to fractionated radiotherapy (123) . As radiotracers require a biologically significant molecule, e.g., a nitroimidazole combined with a radioactive component such as 18 F, it is crucial that the radioisotope does not interfere with the biological properties of the exogenous marker. For example, the lipophilic and hydrophilic balance of the marker is responsible for tracer distribution and clearance of the unbound tracer from the tumor to provide a better tumor to background ratio. Much of radiotracer selection stems from the availability of the tracer, ease of synthesis and tumor type/model. The second challenge is developing a reliable method for tracer validation. PET tracers are often validated against an accepted standard of hypoxia measurement. However, no ''true'' gold standard exists. While the Eppendorf pO 2 electrode is often considered the gold standard, it is limited by user dependence and sampling error (41) . Comparisons have been made against immunohistochemical staining, however, the spatial registration can be challenging. On imaging, necrotic and normoxic regions appear to be the same (no uptake) while some immunohistochemical stains can differentiate between these regions. (124) . Moreover, this highlights one of the fundamental limitations of PET imaging -the discrepancy between the microscopic scale of hypoxia and the macroscopic resolution of the PET voxel. Thus, through imaging we are missing much of heterogeneity of hypoxia by the partial volume effect and large voxel sizes. If we compare the PET voxel to Eppendorf pO 2 values or microscopic immunohistochemical, it is essential to average the measurement values. We also do not know the (125) .
The third obstacle is assessing tracer uptake and the tumor hypoxic fraction in a quantitative and reproducible way. The most commonly used metric is the tumor-to-blood ratio (TBR), which is dependent on an arbitrary 
What is Realistic in a Clinical Setting?
Considering all of these challenges, is it realistic to quantify tumor hypoxia with PET in a clinical setting? [ 18 F]-FMISO uptake, for example, appears to vary across tumor types and sites within the same patient (71, 77, 83) . This inconsistency reduces the hypoxia differentiation of the tracer but may be attributed to the hypoxia definition used, e.g., the maximum standard uptake value (SUV max ) or TBR. Differentiating between hypoxic levels based on TBR can be ambiguous as ratios can vary across patients and tumor types. However, dynamic as opposed to static scanning further elucidates the movement of the tracer from the blood into the tumor and the hypoxic regions. This method provides both temporal and spatial information for the tracer and hypoxia and is more reliable and accurate than the SUV measurement. As a result, static scans are insufficient because a dynamic or early scan is needed to provide information about the input function and the perfusion of the tumor vasculature within the tumor voxels (94, 126) . The Thorwarth model (129), which has been clinically validated (94) , accounts for perfusion, diffusion and binding of the tracer and can distinguish between necrosis and severely hypoxic regions. Monnich et al. (126) proposed a scan at an early time point, 15 min post-injection, and a late scan at 4 h. Ideally, the tracer kinetic model would be sensitive to patient-specific tracer pharmacokinetics, e.g., clearance and metabolite formation. In addition, models must be robust enough to account for large voxel sizes (3-4 mm in each dimension), noise, organ motion and technical challenges associated with image registration. Despite the introduction of kinetic modeling techniques to analyze dynamic PET data, several challenges remain before this analysis technique can become a clinical reality. Perhaps a model that could accommodate a clinically realistic imaging schedule would be better, i.e., to image at an early and late time point and use the model to calculate the hypoxic fraction. Such a model could provide more information on the best imaging time points during radiotherapy (87, 107) . Alternatively, the [ 18 F]-FMISO imaging data could be predictive of response to radiation therapy instead of being used to provide adaptive information (94) .
CONCLUSIONS AND OUTLOOK
It is evident that PET imaging is a powerful tool for visualizing tumor hypoxia in patients in a clinical setting. The feasibility of imaging hypoxia with PET has been clinically demonstrated in a number of cancer types using several existing radiotracers. PET has allowed the prediction of treatment response and demonstrated the potential for optimizing radiotherapy plans. However, due to the complexity of tumor hypoxia, technological advances to combat low image contrast, high noise and poor spatial resolution are needed to improve our ability to routinely quantify the hypoxic fraction in human tumors. Improvements in spatial resolution with PET, MRI or bioluminescent imaging may bring us closer to clinically incorporating the hypoxic fraction of the patient tumor in routine cancer therapy. Moreover, the development of improved tracers and image analysis techniques is essential to provide better hypoxia specificity and quantification metrics. A systematic review of randomized clinical trials demonstrates a clinical benefit of adding hypoxic modification to radiotherapy for head and neck squamous cell carcinomas (130) . This, combined with the advancement of PET imaging techniques and tracer development, along with more in vivo studies, could make PET imaging and hypoxic modification a standard of care in the clinical setting for many cancer types.
